Kimberly-Clark Completes Kenvue Acquisition

Kimberly-Clark’s acquisition of Kenvue closed on November 2, 2026, according to its completion announcement and Form 8-K filing. The company said the combined portfolio includes 10 brands that each generate annual sales of $1 billion or more.

Those brands include Tylenol, Huggies, Neutrogena, Scott and Listerine, along with Kotex, Johnson’s Baby, Cottonelle, Kleenex and Depend, according to Kimberly-Clark.

The filing sets out consideration for each Kenvue share of $3.50 in cash plus 0.14625 shares of Kimberly-Clark stock. Shareholders were entitled to a cash payment rather than any fractional Kimberly-Clark share. According to the filing, the transaction made Kenvue LLC a wholly owned, direct subsidiary of Kimberly-Clark. Trading in Kenvue common stock on the New York Stock Exchange ceased at the opening of the market on November 2, 2026.

Kimberly-Clark said it planned to organize the combined operations into four geographic segments. North America and Europe, Middle East and Africa would be two of them. Asia Pacific Focus Markets would encompass Greater China, South Korea, Indonesia, Australia and New Zealand. Enterprise Markets would cover Japan, India, Latin America and Southeast Asian markets.

The company said its estimate for annual run-rate synergies remained about $2.1 billion. That estimate incorporates approximately $1.9 billion of cost savings expected within three years of closing, plus roughly $500 million in additional profit from revenue synergies expected within four years. About $300 million of reinvestment would partly offset those amounts.

According to the Form 8-K, the Kenvue Integration Program started on November 2, 2026. The filing gives December 31, 2029, as its expected completion date and identifies operating-profit synergies by 2030 as the program’s objective.

For that program, Kimberly-Clark estimated cumulative charges before tax of about $3.1 billion, comprising $2.5 billion in cash charges and $600 million in non-cash charges. Its estimate for related capital expenditure through December 31, 2029, was approximately $1.4 billion. The company said the charges actually incurred, and their timing, could vary from those estimates.

The filing identifies the principal uses of the estimated cash charges as optimization of the supply-chain network and workforce, integration of enterprise resource planning systems and technology, and advisory services. Program management, along with other costs associated with restructuring and integration, also forms part of those estimated charges, according to the company.

* This article is based on publicly available information at the time of writing.